Edwards Urges Full Fed. Circ. To Limit FDA Safe Harbor

By Dani Kass · May 28, 2024, 4:22 PM EDT

Edwards Lifesciences has petitioned the full Federal Circuit to narrow its interpretation of a U.S. Food and Drug Administration safe harbor that essentially allows patent infringement during drug development, arguing that...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Petition

Case Information

Case Title

Edwards Lifesciences Corporation v. Meril Life Sciences Pvt. Ltd.

Case Number

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Qst.)

Date Filed

June 07, 2022

Recent Articles By Dani

April 05, 2024
Judge Lourie's Dissent Revives Debate Over FDA Safe Harbor
February 20, 2024
Fed. Circ. Backs Microsoft's PTAB Win Over 3D Patents
February 08, 2024
HHS Won't Invoke IP Rights To Lessen Xtandi Prices
January 30, 2024
CDC Patent Apps Lead Gilead To Victory In HIV Research Feud
January 11, 2024
NJ Judge Not Convinced Epidiolex Seller Lied To USPTO
December 13, 2023
The Biggest Patent Rulings Of 2023
November 17, 2023
FDA's Lack Of Power May Limit FTC's Patent Challenge
November 02, 2023
Nonprofit Calls For CMS-Amgen Price Talks To Reflect Abuse
October 24, 2023
AliveCor Urges Stay In Calif. While Challenging Apple Patents
August 08, 2023
Fed. Circ. Told Apple Watch Ban Could Turn ITC 'Meaningless'